Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Edeline, J.; Benabdelghani, M.; Bertaut, A.; Watelet, J.; Hammel, P.; Joly, J.; Boudjema, K.; Fartoux, L.; Bouhier‐Leporrier, K.; Jouve, J.; Faroux, R.; Guérin-Meyer, V.; Kurtz, J.; Assenat, E.; Seitz, J.; Baumgaertner, I.; Tougeron, D.; de la Fouchardière, C.; Lombard-Bohas, C.; Boucher, E.; Stanbury, T.; Louvet, C.; Malka, D.; Phelip, J.

doi:10.1200/JCO.18.00050

Public

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Shared by NobleBlocks on Feb 1, 2019 • 12:00 AM UTC

Authors:

J. Edeline

M. Benabdelghani

A. Bertaut

Abstract

PURPOSE No standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether gemcitabine and oxaliplatin chemotherapy (GEMOX) would increase relapse-free survival (RFS) while maintaining health-related quality of life (H...

Subject

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!